Milsaperidone
Major Depressive Disorder (MDD)
Vanda PharmaceuticalsPhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
234 Active assets in the Major Depressive Disorder (MDD) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Risperdal Johns Hopkins University | Phase 4 | BBB |
Zelapar Corium Innovations, Inc. | Phase 4 | BBB |
S-Ketamine Janssen Research & Development, LLC | Phase 4 | BBB |
EDIVOXETINE Eli Lilly and Company | Phase 3 | BBB |
Opc-34712 Nova Scotia Health Authority | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →